Home 2018-07-05T11:36:59+00:00

for a Brighter Tomorrow

JOIN MAILING LIST

PRESENTATION

PIPELINE

INVESTORS

ABOUT US

Oramed Pharmaceuticals (NASDAQ: ORMP) has developed an innovative technology to transform injectable treatments into oral therapies.

Oramed’s flagship product, an oral insulin capsule, has the potential to better the lives of millions of diabetics around the world – allowing, amongst other things, type 2 patients to begin insulin therapy earlier without fear of needles.

Oramed’s oral insulin is currently in advanced clinical trials under the US FDA for both type 1 and type 2 diabetes.

In addition to oral insulin, the company’s proprietary POD™ technology can be used to orally administer a number of protein-based therapies, which are available only via injection.

PRESS RELEASES

Oramed Granted Japanese Patent for GLP-1 Analog Capsule

July 24th, 2018|Comments Off on Oramed Granted Japanese Patent for GLP-1 Analog Capsule

NEW YORK, July 24, 2018 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: [...]

Oramed Announces Closing of $18.1 Million Registered Direct Offering

July 6th, 2018|Comments Off on Oramed Announces Closing of $18.1 Million Registered Direct Offering

NEW YORK, July 6, 2018 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) [...]